High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia

Annals of Oncology

Volumn 11, Issue 8, 2000, Pages 1007-1015

  Rohatiner, A Z S ^a   Bassan, R ^b   Raimondi, R ^c   Amess, J A L ^a   Arnott, S ^a   Personen, A ^b   Rodeghiero, F ^c   Barbui, T ^b   Bradburn, M J ^d   Carter, M ^a   Lister, T A ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b OSPEDALI RIUNITI   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

ABMT; AML; High dose treatment

Indexed keywords

CYTARABINE; DOXORUBICIN; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD CELL COUNT; BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE COUNT; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CYTARABINE; DOXORUBICIN; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEUTROPENIA; PROGNOSIS; SURVIVAL ANALYSIS; THIOGUANINE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 0033798050     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008333903220     Document Type: Article

References (57)

1. Postremission chemotherapy for adults with acute myelogenous leukemia: Improved survival with high-dose cytarabine and daunorubicin consolidation treatment
2. Double intensive consolidation chemotherapy in adult acute myeloid leukemia
3. Varying intensity of postremission therapy in acute myeloid leukemia
4. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission
5. Intensive postremission chemotherapy in adults with acute myeloid leukemia
6. Improved survival for patients with acute myelogenous leukemia
7. Marrow transplantation for acute non-lymphoblastic leukemia in first remission
8. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide, total body irradiation and cyclosporin
9. The combined effect of total body irradiation (TBI) and Cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation
10. Autologous and allogeneic bone marrow transplantation in acute myeloid leukemia in first complete remission: An update of the Genoa experience with 159 patients
11. Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission
12. Autologous bone marrow transplantation in acute myeloid leukemia in first remission. Results of a Dutch prospective study
13. Busulfan etoposide, initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute non-lymphocytic leukemia
14. Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow
15. Autologous bone marrow transplantation for acute myelogenous leukemia, using 4 hydroperoxycyclophosphamide and VP-16 purged bone marrow
16. Autologous bone marrow transplantation in acute myeloid leukemia: The University of Minnesota experience
17. Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in elderly patients: A retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT)
18. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan group for bone marrow transplantation
19. A comparison of busulfan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia
20. Autologous peripheral blood stem-cell transplantation for acute myelogenous leukemia
21. 1993 Progress report from the International Bone Marrow Transplant Registry
22. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group
23. Short-term therapy for acute myelogenous leukaemia
24. Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia
25. Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia
26. Nonparametric estimation from incomplete observations
27. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia
28. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukaemia
29. Randomised comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial
30. Allogeneic vs. autologous stem-cell transplantaion vs. chemotherapy in patients with acute myeloid leukemia in first remission: The BGMT 87 study
31. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission
32. Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation
33. Chromosome abnormalities in acute nonlymphocytic leukemia: Clinical and biologic significance
34. Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome
35. Prognostic significance of karyotype in de novo adult acute myeloid leukemia
36. Do cytogenetics predict outcome of autologous bone marrow transplantation (ABMT) for acute myelogenous leukemia (AML) in first remission (CR)?
37. Impact of diagnostic cytogenetics on outcome in AML: Analysis of 1613 patients entered into the UK MRC AML 10 trial
38. Curative impact of intensification with high-dose Cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group
39. Karyotype in acute myeloblastic leukemia: Prognostic significance in a prospective study assessing bone marrow transplantation in first remission
40. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission
41. Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation Study
42. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial
43. Myeloablative therapy with peripheral blood progenitor cell (PBPC) support as consolidation of first remission in younger patients with acute myelogenous leukaemia (AML)
44. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leuaemic cells
45. In vitro down-regulation of BCL-2 expression by all-trans retinoic acid in AML blasts
46. Retinoids increase idarubicin cytotoxicity in human myeloid leukaemia cell lines
47. Granulocyte macrophage colony stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation
48. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation
49. Post remission therapy for acute myeloid leukemia with blood-derived stem-cell transplantation. Results of a collaborative Phase II trial Int
50. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival with respect to bone marrow cells
51. Busulfan plus cyclophosphamide followed by autologous stem cell transplantation for patients with acute myeloablastic leukaemia in first complete remission: A report from a single institution
52. Autologous stem cell transplantation (APSCT) with G-CSF primed peripheral blood in acute myelogenous leukemia (AML) in first complete remission (CR 1)
53. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine/G-CSF-based consolidation for adults with acute myelogenous leukemia in first complete remission
54. Peripheral blood progenitor cell collection (PBPC) in patients with AML